Targeted therapy for brain tumours:Role of PARP inhibitors

Current Cancer Drug Targets

Volumn 12, Issue 3, 2012, Pages 218-236

  Leonetti, C ^a   Biroccio, A ^a   Graziani, G ^b   Tentori, L ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Angiogenesis; Chemoresistance; Combination therapy; Molecular targeted therapy; Poly(ADP ribose) polymerase (PARP) inhibitors; Telomere; Temozolomide; Topoisomerase i inhibitors

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CARMUSTINE; CETUXIMAB; CILENGITIDE; E 7016; ENZASTAURIN; GPI 21016; GPI 21916; INIPARIB; INO 1001; IRINOTECAN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMOTUZUMAB; NITROSOUREA; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PKI 587; RUCAPARIB; SINGLE STRANDED DNA; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VELIPARIB; VORINOSTAT; XL 765;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BRAIN TUMOR; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL TRIAL; CYTOTOXICITY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GLIOBLASTOMA; HOMOLOGOUS RECOMBINATION; HUMAN; MEDULLOBLASTOMA; MONOTHERAPY; MOOD DISORDER; NAUSEA; NEUTROPENIA; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VOMITING;

EID: 84857130173     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799277403     Document Type: Review

References (243)

1. Huse, J. T.; Holland, E. C. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 2010, 10, 319-331.
2. Gladson, C. L.; Prayson, R. A.; Liu, W. M. The pathobiology of glioma tumors. Annu. Rev. Pathol. 2010, 5, 33-50.
3. Riemenschneider, M. J.; Jeuken, J. W.; Wesseling, P.; Reifenberger, G. Molecular diagnostics of gliomas: state of the art. Acta Neuropathol. 2010, 120, 567-584.
4. Louis, D. N.; Ohgaki, H.; Wiestler, O. D.; Cavenee, W. K.; Burger, P. C.; Jouvet, A.; Scheithauer, B. W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114, 97-109.
5. Niyazi, M.; Siefert, A.; Schwarz, S. B.; Ganswindt, U.; Kreth, F. W.; Tonn, J. C.; Belka, C. Therapeutic options for recurrent malignant glioma. Radiother. Oncol. 2011, 98, 1-14.
6. Brada, M.; Stenning, S.; Gabe, R.; Thompson, L. C.; Levy, D.; Rampling, R.; Erridge, S.; Saran, F.; Gattamaneni, R.; Hopkins, K.; Beall, S.; Collins, V. P.; Lee, S. M. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol. 2010, 28, 4601-4608.
7. La Rocca, R. V.; Mehdorn, H. M. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr. Med. Res. Opin. 2009, 25, 149-160.
8. Anderson, E.; Grant, R.; Lewis, S.; Whittle, I. R. Randomized phase III controlled trials of therapy in malignant glioma: where are we after 40 years? Br. J. Neurosurg. 2008, 22, 339-349.
9. Stewart, L. A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359, 1011-1018.
10. Stupp, R.; Hegi, M. E.; Mason, W. P.; van den Bent, M. J.; Taphoorn, M. J.; Janzer, R. C.; Ludwin, S. K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A. A.; Gijtenbeek, J.; Marosi, C.; Vecht, C. J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J. G.; Mirimanoff, R. O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10, 459-466.
11. Vinjamuri, M.; Adumala, R. R.; Altaha, R.; Hobbs, G. R.; Crowell, E. B. Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients. J. Neurooncol. 2009, 91, 221-225.
12. Stupp, R.; Mason, W. P.; van den Bent, M. J.; Weller, M.; Fisher, B.; Taphoorn, M. J.; Belanger, K.; Brandes, A. A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R. C.; Ludwin, S. K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J. G.; Eisenhauer, E.; Mirimanoff, R. O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
13. Bock, H. C.; Puchner, M. J.; Lohmann, F.; Schütze, M.; Koll, S.; Ketter, R.; Buchalla, R.; Rainov, N.; Kantelhardt, S. R.; Rohde, V.; Giese, A. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg. Rev. 2010, 33, 441-449.
14. Brem, H.; Piantadosi, S.; Burger, P. C.; Walker, M.; Selker, R.; Vick, N. A.; Black, K.; Sisti, M.; Brem, S.; Mohr, G.; Muller, P; Morawetz, R; Schold S.C. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345, 1008-1012.
15. Westphal, M.; Hilt, D. C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P. C.; Whittle, I. R.; Jääskeläinen, J.; Ram, Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003, 5, 79-88.
16. Christmann, M.; Verbeek, B.; Roos, W.P.; Kaina, B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. Biochim. Biophys. Acta 2011, 1816, 179-90.
17. Hegi, M. E.; Diserens, A. C.; Gorlia, T., Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L.; Bromberg, J. E.; Hau, P.; Mirimanoff, R. O.; Cairncross, J. G.; Janzer, R. C.; Stupp, R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352, 997-1003.
18. Hegi, M. E.; Liu, L.; Herman, J. G.; Stupp, R.; Wick, W.; Weller, M.; Mehta, M. P.; Gilbert, M. R. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 2008, 26, 4189-4199.
19. Rivera, A. L.; Pelloski, C. E.; Gilbert, M. R.; Colman, H.; De La Cruz, C.; Sulman, E. P.; Bekele, B. N.; Aldape, K. D. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010, 12, 116-121.
20. van Nifterik, K.A.; van den Berg, J.; van der Meide, W.F.; Ameziane, N.; Wedekind, L.E.; Steenbergen, R.D.; Leenstra, S.; Lafleur, M.V.; Slotman, B.J.; Stalpers, L.J.; Sminia, P. Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br. J. Cancer 2010, 103, 29-35.
21. Kondo, N.; Takahashi, A.; Ono, K.; Ohnishi, T. DNA damage induced by alkylating agents and repair pathways. J. Nucleic Acids 2010, 2010, 543531.
22. Karran, P.; Bignami, M. DNA damage tolerance, mismatch repair and genome instability. Bioessays 1994, 16, 833-839.
23. D'Atri, S.; Tentori, L.; Lacal, P. M.; Graziani, G.; Pagani, E.; Benincasa, E.; Zambruno, G.; Bonmassar, E.; Jiricny, J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. 1998, 54, 334-341.
24. Tentori, L.; Graziani, G. Recent approaches to improve the antitumour efficacy of temozolomide. Curr. Med. Chem. 2009, 16, 245-257.
25. Kat, A.; Thilly, W. G.; Fang, W. H.; Longley, M. J.; Li, G. M.; Modrich, P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 6424-6428.
26. Friedman, H. S.; Johnson, S. P.; Dong Q.; Schold S. C.; Rasheed, B. K.; Bigner, S. H.; Ali-Osman, F.; Dolan, E.; Colvin, O. M.; Houghton, P.; Germain, G.; Drummond, J. T.; Keir, S.; Marcelli, S.; Bigner, D. D.; Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res. 1997, 57, 2933-2936.
27. Wedge, S. R.; Porteous, J. K.; Newlands, E. S. 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer 1996, 74, 1030-1036.
28. Stojic, L.; Brun, R.; Jiricny, J. Mismatch repair and DNA damage signalling. DNA Repair 2004, 3, 1091-1101.
29. Wei, Q.; Bondy, M. L.; Mao, L.; Gaun, Y.; Cheng, L.; Cunningham, J.; Fan, Y.; Bruner, J. M.; Yung, W. K.; Levin, V. A.; Kyritsis, A. P. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res. 1997, 57, 1673-1677.
30. Cahill, D. P.; Codd, P. J.; Batchelor, T. T.; Curry, W. T.; Louis, D. N. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin. Neurosurg. 2008; 55, 165-171.
31. Friedman, H. S.; McLendon, R. E.; Kerby, T.; Dugan, M.; Bigner, S. H.; Henry, A. J.; Ashley, D. M.; Krischer, J.; Lovell, S.; Rasheed, K.; Marchev, F.; Seman, A. J.; Cokgor, I.; Rich, J.; Stewart, E.; Colvin, O. M.; Provenzale, J. M.; Bigner, D. D.; Haglund, M. M.; Friedman, A. H.; Modrich, P. L. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol. 1998, 16, 3851-3857.
32. Sarkaria, J. N.; Kitange, G. J.; James, C. D.; Plummer, R.; Calvert, H.; Weller, M.; Wick, W. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin. Cancer Res. 2008, 14, 2900-2908.
33. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner DD, Friedman HS. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin. Cancer Res. 2008, 14, 4859-4868.
34. Mellinghoff, I. K.; Wang, M. Y.; Vivanco, I.; Haas-Kogan, D. A.; Zhu, S.; Dia, E. Q.; Lu, K. V.; Yoshimoto, K.; Huang, J. H.; Chute, D. J.; Riggs, B. L.; Horvath, S.; Liau, L. M.; Cavenee, W. K.; Rao, P. N.; Beroukhim, R.; Peck, T. C.; Lee, J. C.; Sellers, W. R.; Stokoe, D.; Prados, M.; Cloughesy, T. F.; Sawyers, C. L.; Mischel, P. S. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353, 2012-2024.
35. Brandes, A. A.; Franceschi, E.; Tosoni, A.; Hegi,; M, E,; Stupp, R. Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin. Cancer Res. 2008, 14, 957-960.
36. Thiessen, B.; Stewart, C.; Tsao, M.; Kamel-Reid, S.; Schaiquevich, P.; Mason, W.; Easaw, J.; Belanger, K.; Forsyth, P.; McIntosh, L.; Eisenhauer, E. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother. Pharmacol. 2010, 65, 353-361.
37. Brown, P. D.; Krishnan, S.; Sarkaria, J. N.; Wu, W.; Jaeckle, K. A.; Uhm, J. H.; Geoffroy, F. J.; Arusell, R.; Kitange, G.; Jenkins, R. B.; Kugler, J. W.; Morton, R. F.; Rowland, K. M.; Mischel, P.; Yong, W. H.; Scheithauer, B. W.; Schiff, D.; Giannini, C.; Buckner, J. C.; North Central Cancer Treatment Group Study N0177. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J. Clin. Oncol. 2008, 26, 5603-5609.
38. Prados, M. D.; Chang, S. M.; Butowski, N.; DeBoer, R.; Parvataneni, R.; Carliner, H.; Kabuubi, P.; Ayers-Ringler, J.; Rabbitt, J.; Page, M.; Fedoroff, A.; Sneed, P. K.; Berger, M. S.; McDermott, M. W.; Parsa, A. T.; Vandenberg, S.; James, C. D.; Lamborn, K. R.; Stokoe, D.; Haas-Kogan, D. A. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 2009, 27, 579-584.
39. van den Bent, M. J.; Brandes, A. A.; Rampling, R.; Kouwenhoven, M. C.; Kros, J. M.; Carpentier, A. F.; Clement, P. M.; Frenay, M.; Campone, M.; Baurain, J. F.; Armand, J. P.; Taphoorn, M. J.; Tosoni, A.; Kletzl, H.; Klughammer, B.; Lacombe, D.; Gorlia, T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 2009, 27, 1268-1274.
40. Peereboom, D. M.; Shepard, D. R.; Ahluwalia, M. S.; Brewer, C. J.; Agarwal, N.; Stevens, G. H.; Suh, J. H.; Toms, S. A.; Vogelbaum, M. A.; Weil, R. J.; Elson, P.; Barnett, G. H. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 2010, 98, 93-99.
41. Yiin, J. J.; Hu, B.; Schornack, P. A.; Sengar, R. S.; Liu, K. W.; Feng, H.; Lieberman, F. S.; Chiou, S. H.; Sarkaria, J. N.; Wiener, E. C.; Ma, H. I.; Cheng, S. Y. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol. Cancer Ther. 2010, 9, 929-941.
42. Rich, J. N.; Sathornsumetee, S.; Keir, S. T.; Kieran, M. W.; Laforme, A.; Kaipainen, A.; McLendon, R. E.; Graner, M. W.; Rasheed, B. K.; Wang, L.; Reardon, D. A.; Ryan, A. J.; Wheeler, C.; Dimery, I.; Bigner, D. D.; Friedman, H. S. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res. 2005, 11, 8145-8157.
43. Sandström, M.; Johansson, M.; Andersson, U.; Bergh, A.; Bergenheim, A. T.; Henriksson, R. The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br. J. Cancer 2004, 91, 1174-1180.
44. Drappatz, J.; Norden, A. D.; Wong, E. T.; Doherty, L. M.; Lafrankie, D. C.; Ciampa, A.; Kesari, S.; Sceppa, C.; Gerard, M.; Phan, P.; Schiff, D.; Batchelor, T. T.; Ligon, K. L.; Young, G.; Muzikansky, A.; Weiss, S. E.; Wen, P. Y. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78, 85-90.
45. Broniscer, A.; Baker, J. N.; Tagen, M.; Onar-Thomas, A.; Gilbertson, R. J.; Davidoff, A. M.; Panandiker, A. S.; Leung, W.; Chin, T. K.; Stewart, C. F.; Kocak, M.; Rowland, C.; Merchant, T. E.; Kaste, S. C.; Gajjar, A. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J. Clin. Oncol. 2010, 28, 4762-4768.
46. Neyns, B.; Sadones, J.; Joosens, E.; Bouttens, F.; Verbeke, L.; Baurain, J. F.; D'Hondt, L.; Strauven, T.; Chaskis, C.; Int Veld, P.; Michotte, A.; De Greve, J. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol. 2009, 20, 1596-1603.
47. Ramakrishnan, M. S.; Eswaraiah, A.; Crombet, T.; Piedra, P.; Saurez, G.; Iyer, H.; Arvind, A. S. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009, 1, 41-48.
48. Massimino, M.; Bode, U.; Biassoni, V.; Fleischhack, G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin. Biol. Ther. 2011, 11, 247-256.
49. Pellegatta, S.; Cuppini, L; Finocchiaro, G. Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. Expert Rev. Anticancer Ther. 2011, 11, 1759-1774.
50. Heimberger, A. B.; Sampson, J. H. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin. Biol. Ther. 2009, 9, 1087-1098.
51. Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P. M.; Muzikansky, A.; Loeffler, J. S. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J. Clin. Oncol. 2004, 22, 1926-1933.
52. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human Cancer Nat. Rev. Cancer 2002, 2, 489-501.
53. Fan, Q.W.; Weiss, W.A. Inhibition of PI3K-Akt-mTOR Signaling in Glioblastoma by mTORC1/2 Inhibitors. Methods Mol. Biol. 2012, 821, 349-59.
54. Ohgaki, H. Genetic pathways to glioblastomas. Neuropathology 2005, 25, 1-7.
55. Mladkova, N.; Chakravarti, A. Molecular profiling in glioblastoma: prelude to personalized treatment. Curr. Oncol. Rep. 2009, 11, 53-61.
56. Cook, K. M.; Figg, W. D. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J. Clin. 2010, 60, 222-243.
57. Endersby, R.; Baker, S. J. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 2008, 27, 5416-5630.
58. Fan, Q. W.; Weiss, W. A. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr. Top Microbiol. Immunol. 2010, 347, 279-296.
59. Huang, T. T.; Sarkaria, S. M.; Cloughesy, T. F.; Mischel, P. S. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009, 6, 500-512.
60. Chang, S. M.; Wen, P.; Cloughesy, T.; Greenberg, H.; Schiff, D.; Conrad, C.; Fink, K.; Robins, H. I.; De Angelis, L.; Raizer, J.; Hess, K.; Aldape, K.; Lamborn, K. R.; Kuhn, J.; Dancey, J.; Prados, M. D.; North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs. 2005, 23, 357-361.
61. Galanis, E.; Buckner, J. C.; Maurer, M. J.; Reid, J. M.; Kuffel, M. J.; Ames, M. M.; Scheithauer, B. W.; Hammack, J. E.; Pipoly, G.; Kuross, S. A. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 2005, 23, 5294-5304.
62. Mallon, R.; Feldberg, L.R.; Lucas, J.; Chaudhary, I.; Dehnhardt, C.; Santos, E.D.; Chen, Z.; dos Santos, O.; Ayral-Kaloustian, S.; Venkatesan, A.; Hollander, I. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor Clin. Cancer Res. 2011, 17, 3193-203.
63. Guha, A.; Feldkamp, M. M.; Lau, N.; Boss, G.; Pawson, A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997, 15, 2755-2765.
64. Thaker, N. G.; Pollack, I. F. Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev. Neurother. 2009, 9, 1815-1836.
65. Fouladi, M.; Nicholson, H. S.; Zhou, T.; Laningham, F.; Helton, K. J.; Holmes, E.; Cohen, K.; Speights, R. A.; Wright, J.; Pollack, I. F.; Children's Oncology Group. A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer 2007, 110, 2535-2541.
66. Lustig, R.; Mikkelsen, T.; Lesser, G.; Grossman, S.; Ye, X.; Desideri, S.; Fisher, J.; Wright, J. New Approaches to Brain Tumor Therapy CNS ConsortiumPhase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008, 10, 1004-1009.
67. Cloughesy, T. F.; Wen, P. Y.; Robins, H. I., Chang, S. M.; Groves, M. D.; Fink, K. L.; Junck, L.; Schiff, D.; Abrey, L.; Gilbert, M. R.; Lieberman, F.; Kuhn, J.; DeAngelis, L. M.; Mehta, M.; Raizer, J. J.; Yung, W. K.; Aldape, K.; Wright, J.; Lamborn, K. R.; Prados, M. D. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 2006, 24, 3651-3656.
68. De Witt Hamer, P. C. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol. 2010, 12, 304-316.
69. Sharif, T. R.; Sharif, M. Overexpression of Protein Kinase C epsilon in astroglial brain tumor-derived cell lines and primary tumor samples. Int. J. Oncol. 1999, 15, 237-243.
70. Bredel, M.; Pollack, I. F. The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy. Acta Neurochir. (Wien). 1997, 139, 1000-1013.
71. Balendran, A.; Hare, G. R.; Kieloch, A.; Williams, M. R.; Alessi, D. R. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 2000, 484, 217-223.
72. Mercer, R. W.; Tyler, M. A.; Ulasov, I. V.; Lesniak, M. S. Targeted therapies for malignant glioma: progress and potential. BioDrugs 2009, 23, 25-35.
73. da Rocha, A. B.; Mans, D. R.; Regner, A.; Schwartsmann, G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas? Oncologist 2002, 7, 17-33.
74. Kreisl, T. N.; Kim, L.; Moore, K.; Duic, P.; Kotliarova, S.; Walling, J.; Musib, L.; Thornton, D.; Albert, P. S.; Fine, H. A. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin. Cancer Res. 2009, 15, 3617-3623.
75. Galanis, E.; Jaeckle, K. A.; Maurer, M. J.; Reid, J. M.; Ames, M. M.; Hardwick, J. S.; Reilly, J. F.; Loboda, A.; Nebozhyn, M.; Fantin, V. R.; Richon, V. M.; Scheithauer, B.; Giannini, C.; Flynn, P. J.; Moore, D. F. Jr.; Zwiebel, J.; Buckner, J. C. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J. Clin. Oncol. 2009, 27, 2052-2058.
76. Wolff, J. E.; Kramm, C.; Kortmann, R. D.; Pietsch, T.; Rutkowski, S.; Jorch, N.; Gnekow, A.; Driever, P. H. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J. Neurooncol. 2008, 90, 309-314.
77. Su, J. M.; Li, X. N.; Thompson, P.; Ou, C. N.; Ingle, A. M.; Russell, H. V.; Lau, C. C.; Adamson, P. C.; Blaney, S. M. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS Tumors: A Children's Oncology Group Report. Clin. Cancer Res. 2011, 17, 589-597.
78. Schmidt, N. O.; Westphal, M.; Hagel, C.; Ergün, S.; Stavrou, D.; Rosen, E. M.; Lamszus, K. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer 1999, 84, 10-18.
79. Norden, A. D.; Drappatz, J.; Wen, P. Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008, 7, 1152-1160.
80. Shih, A. H.; Holland, E. C. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006, 232, 139-147.
81. Waugh, D. J.; Wilson, C. The interleukin-8 pathway in cancer Clin. Cancer Res. 2008, 14, 6735-6741.
82. Stefanik, D. F.; Rizkalla, L. R.; Soi, A.; Goldblatt, S. A.; Rizkalla, W. M. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res. 1991, 51, 5760-5765.
83. Brunckhorst, M. K.; Wang, H.; Lu, R.; Yu, Q. Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. Cancer Res. 2010, 70, 7283-7293.
84. Norden, A. D.; Young, G. S.; Setayesh, K.; Muzikansky, A.; Klufas, R.; Ross, G. L.; Ciampa, A. S.; Ebbeling, L. G.; Levy, B.; Drappatz, J.; Kesari, S.; Wen, P. Y. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70, 779-787.
85. Schneider, B. P.; Radovich, M.; Miller, K. D. The role of vascular endothelial growth factor genetic variability in Cancer Clin. Cancer Res. 2009, 15, 5297-5302.
86. Friedman, H. S.; Prados, M. D.; Wen, P. Y.; Mikkelsen, T.; Schiff, D.; Abrey, L. E.; Yung, W. K.; Paleologos, N.; Nicholas, M. K.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 2009, 27, 4733-4740.
87. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E.; Marcello, J.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D. D.; Friedman, A. H.; Friedman, H. S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25, 4722-4729.
88. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E.; Dowell, J. M.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M.; Bigner, D. D.; Friedman, A. H.; Friedman, H. S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13, 1253-1259.
89. Lai, A.; Tran, A.; Nghiemphu, P. L.; Pope, W. B.; Solis, O. E.; Selch, M.; Filka, E.; Yong, W. H.; Mischel, P. S.; Liau, L. M.; Phuphanich, S.; Black, K.; Peak, S.; Green, R. M.; Spier, C. E.; Kolevska, T.; Polikoff, J.; Fehrenbacher, L.; Elashoff, R.; Cloughesy, T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2011, 29, 142-148.
90. Zhang, Y.; Guessous, F.; Kofman, A.; Schiff, D.; Abounader, R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010, 13, 112-121.
91. Hainsworth, J.D.; Ervin, T.; Friedman, E.; Priego, V; Murphy, P.B.; Clark, B.L.; Lamar, R.E. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 2010, 116, 3663-3669.
92. N. Anti-angiogenic therapy in glioma. Clin. Transl. Oncol. 2011, 13, 294-300.
93. Tentori, L.; Dorio, A. S.; Muzi, A.; Lacal, P. M.; Ruffini, F.; Navarra, P.; Graziani, G. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. Oncol. Rep. 2008, 19, 1039-1043.
94. Stupp, R.; Hegi, M. E.; Neyns, B.; Goldbrunner, R.; Schlegel, U.; Clement, P. M.; Grabenbauer, G. G.; Ochsenbein, A. F.; Simon, M.; Dietrich, P. Y.; Pietsch, T.; Hicking, C.; Tonn, J. C.; Diserens, A. C.; Pica, A.; Hermisson, M.; Krueger, S.; Picard, M.; Weller, M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28, 2712-2718.
95. Achanta, P.; Sedora Roman, N. I.; Quiñones-Hinojosa, A. Gliomagenesis and the use of neural stem cells in brain tumor treatment. Anticancer Agents Med. Chem. 2010, 10, 121-130.
96. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; De Vitis, S.; Fiocco, R.; Foroni, C.; Dimeco, F.; Vescovi, A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64, 7011-7021.
97. Singh, S. K.; Clarke, I. D.; Terasaki, M.; Bonn, V. E.; Hawkins, C.; Squire, J.; Dirks, P. B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63, 5821-5828.
98. Ulasov, I. V.; Nandi, S.; Dey, M.; Sonabend, A. M.; Lesniak, M. S. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol. Med. 2011, 17, 103-112.
99. Beauchamp, E. M.; Ringer, L.; Bulut, G.; Sajwan, K. P.; Hall, M. D.; Lee, Y. C.; Peaceman, D.; Ozdemirli, M.; Rodriguez, O.; Macdonald, T. J.; Albanese, C.; Toretsky, J. A.; Uren, A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J. Clin. Invest. 2011, 121,148-160.
100. Low, J. A.; de Sauvage, F. J. Clinical experience with Hedgehog pathway inhibitors. J. Clin. Oncol. 2010, 28, 5321-5326.
101. Enguita-Germán, M.; Schiapparelli, P.; Rey, J. A.; Castresana, J. S. CD133+ cells from medulloblastoma and PNET cell lines are more resistant to cyclopamine inhibition of the sonic hedgehog signaling pathway than CD133- cells. Tumour Biol. 2010, 31, 381-390.
102. Katoh, Y.; Katoh, M. Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9, 873-886.
103. Shi, L.; Zhang, S.; Feng, K.; Wu, F.; Wan, Y.; Wang, Z.; Zhang, J.; Wang, Y.; Yan, W.; Fu, Z.; You, Y. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int. J. Oncol. 2012, 40, 119-29.
104. Cloughesy, T. F.; Mischel, P. S. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin. Cancer Res. 2011, 17, 6-11
105. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol. Cancer 2010, 1, 9-135.
106. Van Meir, E. G.; Hadjipanayis, C. G.; Norden, A. D.; Shu, H. K.; Wen, P. Y.; Olson, J. J. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin.2010,60, 166-193.
107. Minniti, G.; Muni, R.; Lanzetta, G.; Marchetti, P.; Enrici, R. M. Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res. 2009, 29, 5171-5184.
108. Ueno, M.; Nakagawa, T.; Wu, B.; Onodera, M.; Huang, C. L.; Kusaka, T.; Araki, N.; Sakamoto, H. Transporters in the brain endothelial barrier. Curr. Med. Chem. 2010, 17, 1125-1138.
109. Ronellenfitsch, M. W.; Steinbach, J. P.; Wick, W. Epidermal growth factor receptor and mammalian target of rapamycin as therapeutic targets in malignant glioma: current clinical status and perspectives. Target Oncol. 2010, 5, 183-191.
110. Bullock, K. E.; Petros, W. P.; Younis, I.; Uronis, H. E.; Morse, M. A.; Blobe, G. C.; Yousuf Zafar, S.; Gockerman, J. P.; Lager, J. J.; Truax, R.; Meadows, K. L.; Howard, L. A.; O'Neill, M. M.; Broadwater, G.; Hurwitz, H. I; Bendell, J. C. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother. Pharmacol.2011,67, 465-474.
111. Robertson, P. L.; Muraszko, K. M.; Holmes, E. J.; Sposto, R.; Packer, R. J.; Gajjar, A.; Dias, M. S.; Allen, J. C.; Children's Oncology Group. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J. Neurosurg. 2006, 105, 444-451.
112. Grau, C.; Overgaard, J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36, 515-517.
113. P. N. Post-radiation sensorineuronal hearing loss. Int. J. Radiat. Oncol. Biol. Phys. 2002, 52, 589-591.
114. Merchant, T. E.; Kiehna, E. N.; Li, C.; Shukla, H.; Sengupta, S.; Xiong, X.; Gajjar, A.; Mulhern, R. K. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 210-221.
115. Ricardi, U.; Corrias, A.; Einaudi, S.; Genitori, L.; Sandri, A.; di Montezemolo, L. C.; Besenzon, L.; Madon, E.; Urgesi, A. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 1287-1294.
116. Bowers, D. C.; Liu, Y.; Leisenring, W.; McNeil, E.; Stovall, M.; Gurney, J. G.; Robison, L. L.; Packer, R. J.; Oeffinger, K. C. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 2006, 24, 5277-5282.
117. Neglia, J. P.; Robison, L. L.; Stovall, M.; Liu, Y.; Packer, R. J.; Hammond, S.; Yasui, Y.; Kasper, C. E.; Mertens, A. C.; Donaldson, S. S.; Meadows, A. T.; Inskip, P. D. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 2006, 98, 1528-1537.
118. Pollack, I.F. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J. Neurosurg. Pediatr. 2011, 8, 135-48.
119. Rutkowski, S.; Cohen, B.; Finlay, J.; Luksch, R.; Ridola, V.; Valteau-Couanet, D.; Hara, J.; Garre, M. L.; Grill, J. Medulloblastoma in young children. Pediatr. Blood Cancer 2010, 54, 635-637.
120. Borgelt, G.; Gelber, R.; Kramer, S.; Brady, L. W.; Chang, C. H.; Davis, L. W.; Perez, C. A.; Hendrickson, F. R. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int. J. Radiat. Oncol. Biol. Phys. 1980, 6, 1-9.
121. Borgelt, B.; Gelber, R.; Larson, M.; Hendrickson, F.; Griffin, T.; Roth, R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int. J. Radiat. Oncol. Biol. Phys. 1981, 7, 1633-1638.
122. Priestman, T. J.; Dunn, J.; Brada, M.; Rampling, R.; Baker, P. G. Final results of the royal college of radiologists' trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin. Oncol. 1996, 8, 308-315.
123. Mehta, M. P.; Shapiro, W. R.; Phan, S. C.; Gervais, R.; Carrie, C.; Chabot, P.; Patchell, R. A.; Glantz, M. J.; Recht, L.; Langer, C.; Sur, R. K.; Roa, W. H.; Mahe, M. A.; Fortin, A.; Nieder, C.; Meyers, C. A.; Smith, J. A.; Miller, R. A.; Renschler, M. F. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 1069-1076.
124. Mehta, M. P.; Paleologos, N. A.; Mikkelsen, T.; Robinson, P. D.; Ammirati, M.; Andrews, D. W.; Asher, A. L.; Burri, S. H.; Cobbs, C. S.; Gaspar, L. E.; Kondziolka, D.; Linskey, M. E.; Loeffler, J. S.; McDermott, M.; Olson, J. J.; Patchell, R. A.; Ryken, T. C.; Kalkanis, S. N. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96, 71-83.
125. Schreiber, V.; Dantzer, F.; Ame, J. C.; de Murcia, G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell. Biol. 2006, 7, 517-528.
126. Amé, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. Bioessays 2004, 26, 882-893.
127. Malanga, M.; Althaus, F. R. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem. Cell. Biol. 2005, 83, 354-364.
128. Tentori, L.; Graziani, G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. 2005, 52, 25-33.
129. Rouleau, M.; Patel, A.; Hendzel, M. J.; Kaufmann, S. H.; Poirier, G. G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10, 293-301.
130. Drew, Y.; Mulligan, E. A.; Vong, W. T.; Thomas, H. D.; Kahn, S.; Kyle, S.; Mukhopadhyay, A.; Los, G.; Hostomsky, Z.; Plummer, E. R.; Edmondson, R. J.; Curtin, N. J. Therapeutic potential of Poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl. Cancer Inst. 2010, 103, 334-46
131. Dawood, S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010, 70, 2247-2258.
132. Anders, C. K.; Winer, E. P.; Ford, J. M.; Dent, R.; Silver, D. P.; Sledge, G. W.; Carey, L. A. Poly(ADP-Ribose) polymerase inhibition: Targeted therapy for triple-negative breast Cancer Clin. Cancer Res. 2010, 16, 4702-4710.
133. Telli, M. L.; Ford, J. M. PARP Inhibitors in Breast Cancer Clin. Adv. Hematol. Oncol. 2010, 8, 629-635.
134. O'Shaughnessy, J.; Osborne, C.; Pippen, J. E.; Yoffe, M.; Patt, D.; Rocha, C.; Koo, I. C.; Sherman, B. M.; Bradley, C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer N. Engl. J. Med. 2011, 364, 205-214.
135. Chan, S. L.; Mok, T. PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet 2010, 376, 211-213.
136. Comen, E. A.; Robson, M. Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J. 2010, 16, 48-52.
137. Tentori, L.; Turriziani, M.; Franco, D.; Serafino, A.; Levati, L.; Roy, R.; Bonmassar, E.; Graziani, G. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 1999, 13, 901-909.
138. Tentori, L.; Portarena, I.; Vernole, P.; De Fabritiis, P.; Madaio, R.; Balduzzi, A.; Roy, R.; Bonmassar, E.; Graziani, G. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother. Pharmacol. 2001, 47, 361-369.
139. Tentori, L.; Portarena, I.; Torino, F.; Scerrati, M.; Navarra, P.; Graziani, G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 2002, 40, 44-54.
140. Tentori, L.; Leonetti, C.; Scarsella, M.; D'Amati, G.; Vergati, M.; Portarena, I.; Xu, W.; Kalish, V.; Zupi, G.; Zhang, J.; Graziani, G. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumour activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 2003, 9, 5370-5379.
141. Middlemas, D. S.; Stewart, C. F.; Kirstein, M. N.; Poquette, C.; Friedman, H. S.; Houghton, P. J.; Brent, T. P. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin. Cancer Res. 2000, 6, 998-1007.
142. Quiros, S.; Roos, W. P.; Kaina B. Rad51 and BRCA2 - New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One. 2011, 6:e27183-27183.
143. Delaney, C. A.; Wang, L. Z.; Kyle, S.; White, A. W.; Calvert, A. H.; Curtin, N. J.; Durkacz, B. W.; Hostomsky, Z.; Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 2000, 6, 2860-2867.
144. Miknyoczki, S. J.; Jones-Bolin, S.; Pritchard, S.; Hunter, K.; Zhao, H.; Wan, W.; Ator, M.; Bihovsky, R.; Hudkins, R.; Chatterjee, S.; Klein-Szanto, A.; Dionne, C.; Ruggeri, B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2003, 2, 371-382.
145. Calabrese, C. R.; Almassy, R.; Barton, S.; Batey, M. A.; Calvert, A. H.; Canan-Koch, S.; Durkacz, B. W.; Hostomsky, Z.; Kumpf, R. A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D. R.; Notarianni, E.; Stratford, I. J.; Skalitzky, D.; Thomas, H. D.; Wang, L. Z.; Webber, S. E.; Williams, K. J.; Curtin, N. J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 2004, 96, 56-67.
146. Tentori, L.; Leonetti, C.; Scarsella, M.; Muzi, A.; Mazzon, E.; Vergati, M.; Forini, O.; Lapidus, R.; Xu, W.; Dorio, A. S.; Zhang, J.; Cuzzocrea, S.; Graziani, G. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. 2006, 20, 1709-1711.
147. Cimmino, G.; Pepe, S.; Laus, G.; Chianese, M.; Prece, D.; Penitente, R.; Quesada, P. Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines. Pharmacol. Res. 2007, 55, 49-56.
148. Grabenbauer, G. G.; Gerber, K. D.; Ganslandt, O.; Richter, A.; Klautke, G.; Birkmann J.; Meyer, M. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75, 164-169.
149. Xu, T.; Chen, J.; Lu, Y.; Wolff, J. E. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 2010, 10, 252.
150. Wang J. C. Cellular role of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 2002, 3, 430-440.
151. Yung, T. M. C.; Sato, S.; Satoh, M. S. Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating Poly(ADPR)polymerase-1 Topoisomerase I interaction. J. Biol. Chem. 2004, 38, 39686-39696.
152. Malanga, M.; Althaus, F. R. Poly(ADPribose) reactivates stalled DNA topoisomerase I and induces DNA strand breaks resealing. J. Biol. Chem. 2004, 279, 5244-5248.
153. Tentori, L.; Leonetti, C.; Scarsella, M.; d'Amati, G.; Portarena, I.; Zupi, G.; Bonmassar, E.; Graziani, G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing haematologic malignancy at the central nervous system site. Blood 2002, 99, 2241-2244.
154. Tentori, L.; Leonetti, C.; Scarsella, M.; Vergati, M.; Xu, W.; Calvin, D.; Morgan, L.; Tang, Z.; Woznizk, K.; Alemu, C.; Hoover, R.; Lapidus, R.; Zhang, J.; Graziani, G. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumours. Int. J. Oncol. 2005, 26, 415-422.
155. Cheng, C. L.; Johnson, S. P.; Keir, S. T.; Quinn, J. A.; Ali-Osman, F.; Szabo, C.; Li, H.; Salzman, A. L.; Dolan, M. E.; Modrich, P.; Bigner, D. D.; Friedman, H. S. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer Ther. 2005, 4, 1364-1368.
156. Donawho, C. K.; Luo, Y.; Luo, Y.; Penning, T. D.; Bauch, J. L.; Bouska, J. J.; Bontcheva-Diaz, V. D.; Cox, B. F.; DeWeese, T. L.; Dillehay, L. E.; Ferguson, D. C.; Ghoreishi-Haack, N. S.; Grimm, D. R.; Guan, R.; Han, E. K. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 2007, 13, 2728-2737.
157. Liu, X.; Shi, Y.; Guan, R.; Donawho, C.; Luo, Y.; Palma, J.; Zhu, G. D.; Johnson, E. F.; Rodriguez, L. E.; Ghoreishi-Haack, N.; Jarvis, K., Hradil, V. P.; Colon-Lopez, M.; Cox, B. F.; Klinghofer, V.; Penning, T.; Rosenberg, S. H.; Frost, D.; Giranda, V. L.; Luo, Y. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol. Cancer Res. 2008, 6, 1621-1629.
158. Palma, J. P.; Wang, Y. C.; Rodriguez, L. E.; Montgomery, D.; Ellis, P. A.; Bukofzer, G.; Niquette, A.; Liu, X.; Shi, Y.; Lasko, L.; Zhu, G. D.; Penning, T. D.; Giranda, V. L.; Rosenberg, S. H.; Frost, D. J.; Donawho, C. K. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin. Cancer Res. 2009, 15, 7277-7290.
159. Daniel, R. A.; Rozanska, A. L.; Mulligan, E. A.; Drew, Y.; Thomas, H. D.; Castelbuono, D. J.; Hostomsky, Z.; Plummer, E. R.; Tweddle, D. A.; Boddy, A. V.; Clifford, S. C.; Curtin, N. J. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br. J. Cancer 2010, 103, 1588-1596.
160. Godon, C.; Cordelieres, F. P.; Biard, D.; Giocanti, N.; Mégnin-Chanet, F.; Hall, J.; Favaudon, V. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 2008, 36, 4454-4464.
161. Noel, G.; Godon, C.; Fernet, M.; Giocanti, N.; Mégnin-Chanet, F.; Favaudon, V. Radiosensitization by the poly(ADPribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol. Cancer Ther. 2006, 5, 564-574.
162. Dungey, F. A.; Loser, D. A.; Chalmers, A. J. Replication- dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase:replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: Mechanisms and therapeutic Int. J. Radiat. Biol. Phys. 2008, 72, 1188-1197,
163. Albert, J. M.; Cao, C.; Kim, K. W.; Willey, C. D.; Geng, L.; Xiao, D.; Wang, H.; Sandler, A.; Johnson, D. H.; Colevas, A. D.; Low, J.; Rothenberg, M. L.; Lu, B. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 2007, 13, 3033-3042.
164. Ali, M.; Telfer, B. A.; McCrudden, C.; O'Rourke, M.; Thomas, H. D.; Kamjoo, M.; Kyle, S.; Robson, T.; Shaw, C.; Hirst, D. G.; Curtin, N. J.; Williams, K. J. Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: A contributory factor to chemopotentiation in vivo? Clin. Cancer Res. 2009, 15, 6106-6112.
165. Rong, Y.; Durden, D. L.; Van Meir, E. G.; Brat, D. J. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J. Neuropathol. Exp. Neurol. 2006, 65, 529-539.
166. Ruscetti, T.; Lehnert, B. E.; Halbrook, J.; Le Trong, H.; Hoekstra, M. F.; Chen, D. J.; Peterson, S. R. Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase. J. Biol. Chem. 1998, 273, 14461-14467.
167. Bennardo, N.; Cheng, A.; Huang, N.; Stark, J. M. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008, 4, e1000110.
168. A. J. Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med. Chem. 2010, 10, 520-533.
169. Wang, M.; Wu, W.; Wu, W.; Rosidi, B.; Zhang, L.; Wang, H.; Iliakis, G. PARP-1 and ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 2006, 34, 6170-6182.
170. Loser, D. A.; Shibata, A.; Shibata, A. K.; Woodbine, L. J.; Jeggo, P. A.; Chalmers, A. J. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol. Cancer Ther. 2010, 9, 1775-1787.
171. Schlicker, A.; Peschke, P.; Burkle, A.; Hahn, E. W.; Kim, J. H. Four-amino-1,8-naphthalimide: A novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int. J. Radiat. Biol. 1999, 75, 91-100.
172. Khan, K.; Araki, K.; Wang, D.; Li, G.; Li, X.; Zhang, J.; Xu, W.; Hoover, R. K.; Lauter, S.; O'Malley, B., Lapidus, RG.; Li, D. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010, 32, 381-391.
173. Russo, A. L.; Kwon, H. C.; Burgan, W. E.; Carter, D.; Beam, K.; Weizheng, X.; Zhang, J.; Slusher, B. S.; Chakravarti, A.; Tofilon, P. J.; Camphausen, K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin. Cancer Res. 2009, 15, 607-612.
174. Farmer, H.; McCabe, N.; Lord, C. J.; Tutt, A. N.; Johnson, D. A.; Richardson, T. B.; Santarosa, M.; Dillon, K. J.; Hickson, I.; Knights, C.; Martin, N. M.; Jackson, S. P.; Smith, G. C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
175. Bryant, H. E.; Schultz, N.; Thomas, H. D.; Parker, K. M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N. J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434, 913-917.
176. Jasin, M. Homologous repair of DNA damage and tumorigenesis:the BRCA connection. Oncogene 2002, 21, 8981-8993.
177. Underhill, C.; Toulmonde, M.; Bonnefoi, H. A review of PARP inhibitors: from bench to bedside. Ann. Oncol. 2010, doi: 10.1093/annonc/mdq322.
178. Annunziata, C. M.; O'Shaughnessy, J. Poly (adp-ribose) polymerase as a novel therapeutic target in Cancer Clin. Cancer Res. 2010, 16, 4517-4526.
179. Elmariah, S. B.; Huse, J.; Mason, B.; Leroux, P.; Lustig, R. A. Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer. Breast J. 2006, 12, 470-474.
180. Piccirilli, M.; Salvati, M.; Bistazonni, S.; Frati, A.; Brogna, C.; Giangaspero, F.; Frati, R.; Santoro, A. Glioblastoma multiforme and breast cancer: report on 11 cases and clinico-pathologic remarks. Tumori 2005, 91, 256-260.
181. Heitz, F.; Harter, P.; Ewald-Riegler, N.; Papsdorf, M.; Kommoss, S.; du Bois, A. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. Expert Rev. Anticancer Ther. 2010, 10, 1125-1136.
182. Li, L.; Ross, A. H. Why is PTEN an important tumor suppressor? J. Cell Biochem. 2007, 102, 1368-13674.
183. Shen, W. H.; Balajee, A. S.; Wang, J.; Wu, H.; Eng, C.; Pandolfi, P. P.; Yin, Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128, 157-170.
184. Mendes-Pereira, A. M.; Martin, S. A.; Brough, R.; McCarthy, A.; Taylor, J. R.; Kim, J. S.; Waldman, T.; Lord, C. J.; Ashworth, A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1, 315-322.
185. Ramaswamy, S.; Nakamura, N.; Vazquez, F.; Batt, D. B.; Perera, S.; Roberts, T. M.; Sellers, W. R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 2110-2115.
186. Yin, Y.; Shen, W. H. PTEN: a new guardian of the genome. Oncogene 2008, 27, 5443-5453.
187. McEllin, B.; Camacho, C. V.; Mukherjee, B.; Hahm, B.; Tomimatsu, N.; Bachoo, R. M.; Burma, S. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 2010, 70, 5457-5464.
188. Edwards, S. L.; Brough, R.; Lord, C. J.; Natrajan, R.; Vatcheva, R.; Levine, D. A.; Boyd, J.; Reis-Filho, J. S.; Ashworth, A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008, 451, 1111-1115.
189. Norquist, B.; Wurz, K. A.; Pennil, C. C.; Garcia, R.; Gross, J.; Sakai, W.; Karlan, B. Y.; Taniguchi T.; Swisher, E. M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29, 3008-15.
190. Sakai, W.; Swisher, E. M.; Karlan, B. Y.; Agarwal, M. K.; Higgins, J.; Friedman, C.; Villegas, E.; Jacquemont, C.; Farrugia, D. J.; Couch, F. J.; Urban, N.; Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451, 1116-1120.
191. Sakai. W.; Swisher, E. M.; Jacquemont, C.; Chandramohan, K. V.; Couch, F.J.; Langdon, S. P.; Wurz, K.; Higgins, J.; Villegas, E.; Taniguchi, T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009, 69, 6381-6386.
192. Gottipati, P.; Vischioni, B.; Schultz, N.; Solomons, J.; Bryant, H. E.; Djureinovic, T.; Issaeva, N.; Sleeth, K.; Sharma, R. A.; Helleday, T. Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010, 70, 5389-5398.
193. Mukhopadhyay, A.; Elattar, A.; Cerbinskaite, A.; Wilkinson, S. J.; Drew, Y.; Kyle, S.; Los, G.; Hostomsky, Z.; Edmondson, R. J.; Curtin, N. J. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 2010, 16, 2344-2351.
194. Ossovskaya, V.; Koo, I. C.; Kaldjian, E. P.; Alvares, C.; Sherman, B. M. Upregulation of poly (ADP-Ribose) polymerase-1 (PARP1) in triple-negative breast cancer and other primary human tumor types. Genes Cancer 2010, 1, 812-21.
195. Liu, X.; Han, E. K.; Anderson, M.; Shi, Y.; Semizarov, D.; Wang, G.; McGonigal, T.; Roberts, L.; Lasko, L.; Palma, J.; Zhu, G. D.; Penning, T.; Rosenberg, S.; Giranda, V. L.; Luo, Y.; Leverson, J.; Johnson, E. F.; Shoemaker, A. R. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways. Mol. Cancer Res. 2009, 7, 1686-1692.
196. Rottenberg, S.; Jaspers, J. E.; Kersbergen, A.; van der Burg, E.; Nygren, A. O.; Zander, S. A.; Derksen, PW.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O'Connor, M. J.; Martin, N. M.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 17079-17084.
197. Issaeva, N.; Thomas, H. D.; Djureinovic, T., Jaspers, J. E.; Stoimenov, I.; Kyle, S.; Pedley, N.; Gottipati, P.; Zur, R.; Sleeth, K.; Chatzakos, V.; Mulligan, E. A.; Lundin, C.; Gubanova, E.; Kersbergen, A.; Harris, A. L.; Sharma, R. A.; Rottenberg, S.; Curtin, N. J.; Helleday, T. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 2010, 70, 6268-6276.
198. Veres, B.; Gallyas, F.; Varbiro, G.; Berente, Z.; Osz, E.; Szekeres, G.; Szabo, C.; Sumegi, B. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem. Pharmacol. 2003, 65, 1115-1128.
199. Veres, B.; Radnai, B.; Gallyas, F.; Varbiro, G.; Berente, Z.; Osz, E.; Sumegi, B. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J. Pharm. Exp. Ther. 2004, 310, 247-255.
200. Tapodi, A.; Debreceni, B.; Hanto, K.; Bognar, Z., Wittman, I.; Gallyas, F.; Varbiro, G.; Sumegi, B. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J. Biol. Chem. 2005, 280, 35767-35775.
201. Szanto, A.; Hellebrand, E. E.; Bognar, Z.; Tucsek, Z.; Szabo, A.; Gallyas, F.; Sumegi, B.; Varbiro, G. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem. Pharmacol. 2009, 77, 1348-1357.
202. de Soto, J. A.; Deng, C. X. PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? Int. J. Med. Sci. 2006, 3, 117-123.
203. Bryant, H. E.; Helleday, T. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem. Soc. Trans. 2004, 32, 959-961.
204. Gallmeier, E.; Kern, S. E. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol. Ther. 2005, 4, 703-706.
205. Palma, J. P.; Rodriguez, L. E.; Bontcheva-Diaz, V. D.; Bouska, J. J.; Bukofzer, G.; Colon-Lopez, M.; Guan, R.; Jarvis, K.; Johnson, E. F.; Klinghofer, V.; Liu, X.; Olson, A.; Saltarelli, M. J.; Shi, Y.; Stavropoulos, J. A.; Zhu, G. D.; Penning, T. D.; Luo, Y.; Giranda, V. L.; Rosenberg, S. H.; Frost, D. J.; Donawho, C. K. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res. 2008, 28, 2625-2635.
206. Miknyoczki, S.; Chang, H.; Grobelny, J.; Pritchard, S.; Worrell, C.; McGann, N.; Ator, M.; Husten, J.; Deibold, J.; Hudkins, R.; Zulli, A.; Parchment, R.; Ruggeri, B. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther. 2007, 6, 2290-2302.
207. Calabrese, C. R.; Batey, M. A.; Thomas, H. D.; Durkacz, B. W.; Wang, L. Z.; Kyle, S.; Skalitzky, D.; Li, J.; Zhang, C.; Boritzki, T.; Maegley, K.; Calvert, A. H.; Hostomsky, Z.; Newell, D. R.; Curtin, N. J. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. 2003, 9, 2711-2718.
208. Thomas, H. D.; Calabrese, C. R.; Batey, M. A.; Canan, S.; Hostomsky, Z.; Kyle, S.; Maegley, K. A.; Newell, D. R.; Skalitzky, D.; Wang, L. Z.; Webber, S. E.; Curtin, N. J. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 2007, 6, 945-956.
209. Plummer, R.; Jones, C.; Middleton, M.; Wilson, R.; Evans, J.; Olsen, A.; Curtin, N.; Boddy, A.; McHugh, P.; Newell, D.; Harris, A.; Johnson, P.; Steinfeldt, H.; Dewji, R.; Wang, D.; Robson, L.; Calvert, H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 7917-7923.
210. Jones, C.; Plummer, E. R. PARP inhibitors and cancer therapy -early results and potential applications. Br. J. Radiol. 2008, 81, 1, S2-S5.
211. Quinn, J. A.; Pluda, J.; Dolan, M. E.; Delaney, S.; Kaplan, R.; Rich, J. N.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Colvin, O. M.; Haglund, M. M.; Pegg, A. E.; Moschel, R. C.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 2002, 20, 2277-2283.
212. Ryan, C. W.; Dolan, M. E.; Brockstein, B. B.; McLendon, R.; Delaney, S. M.; Samuels, B. L.; Agamah, E. S.; Vokes, E. E. A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemother. Pharmacol. 2006, 58, 634-639.
213. Ranson, M.; Hersey, P.; Thompson, D.; Beith, J.; McArthur, G. A.; Haydon, A.; Davis, I. D.; Kefford, R. F.; Mortimer, P.; Harris, P. A.; Baka, S.; Seebaran, A.; Sabharwal, A.; Watson, A. J.; Margison, G. P.; Middleton, M. R. A randomised trial of the combination of lomeguatrib and temozolomide alone in patients with advanced melanoma. J. Clin. Oncol. 2007, 25, 2540-2545.
214. Morrow, D. A.; Brickman, C. M.; Murphy, S. A.; Baran, K.; Krakover, R.; Dauerman, H.; Kumar, S.; Slomowitz, N.; Grip, L.; McCabe, C. H.; Salzman, A. L. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis 2009, 27, 359-364.
215. Bedikian, A. Y.; Papadopoulos, N. E.; Kim, K. B.; Hwu, W. J.; Homsi, J.; Glass, M. R.; Cain, S.; Rudewicz, P.; Vernillet, L.; Hwu, P. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009, 27, 756-763.
216. Drew, Y.; Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat. 2009, 12, 153-156.
217. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M., Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361, 123-134.
218. Tutt, A.; Robson, M.; Garber, J. E.; Domchek, S. M.; Audeh, M. W.; Weitzel, J. N.; Friedlander, M.; Arun, B.; Loman, N.; Schmutzler, R. K.; Wardley, A.; Mitchell, G.; Earl, H.; Wickens, M.; Carmichael, J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376, 235-244.
219. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376, 245-251.
220. Guhal, M. PARP inhibitors stumble in breast cancer Nature Biotechnol. 2011, 29, 373-374.
221. Mendeleyev, J.; Kirsten, E.; Hakam, A.; Buki, K. G.; Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol. 1995, 50, 705-14.
222. Chalmers, A. J. The potential role and application of PARP inhibitors in cancer treatment. Br. Med. Bull. 2009, 89, 23-40.
223. Wright, W. E.; Tesmer, V. M.; Huffman, K. E.; Levene, S. D. and Shay, J. W. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 1997, 11, 2801-2809.
224. Makarov, V. L.; Hirose, Y.; Langmore, J. P. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997, 88, 657-666.
225. McElligott, R.; Wellinger RJ. The terminal DNA structure of mammalian chromosomes. EMBO J. 1997, 16, 3705-3714.
226. Monchaud, D.; Teulade-Fichou, M. P. A hitchhiker's guide to G-quadruplex ligands. Org. Biomol. Chem. 2008, 6, 627-636.
227. Kelland, L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin. Cancer Res. 2007, 13, 4960-4963.
228. Oganesian, L.; Bryan, T. M. Physiological relevance of telomeric G-quadruplex formation: a potential drug target. Bioessays 2007, 29, 155-165.
229. Gavathiotis, E.; Heald, R. A.; Stevens M. F. G.; Searle, M. S. Drug recognition and stabilisation of the parallel-stranded DNA quadruplex d(TTAGGGT)4 containing the human telomeric repeat. J. Mol. Biol. 2003, 334, 25-36.
230. Rizzo, A.; Salvati, E.; Porru, M.; D'Angelo, C.; Stevens, M. F.; D'Incalci, M.; Leonetti, C.; Gilson, E.; Zupi, G.; Biroccio, A. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATMsignaling pathway. Nucleic Acids Res. 2009, 37, 5353-5364.
231. Salvati, E.; Leonetti, C.; Rizzo, A.; Scarsella, M.; Mottolese, M.; Galati, R.; Sperduti, I.; Stevens, M. F.; D'Incalci, M.; Blasco, M.; Chiorino, G.; Bauwens, S.; Horard, B.; Gilson, E.; Stoppacciaro, A.; Zupi, G.; Biroccio A. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest. 2007, 117, 3236-3247.
232. Leonetti, C.; Scarsella, M.; Riggio, G.; Rizzo, A.; Salvati, E., D'Incalci, M.; Staszewsky, L.; Frapolli, R.; Stevens, M. F.; Stoppacciaro, A.; Mottolese, M.; Antoniani, B.; Gilson, E.; Zupi, G.; Biroccio, A. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin. Cancer Res. 2008, 14, 7284-7291.
233. Salvati, E.; Scarsella, M.; Porru, M.; Rizzo, A.; Iachettini, S.; Tentori, L.; Graziani, G.; D'Incalci, M.; Stevens, M. F.; Orlandi, A.; Passeri, D.; Gilson, E.; Zupi, G.; Leonetti, C.; Biroccio, A. PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene 2010, 29, 6280-6293.
234. Salmena, L.; Carracedo, A.; Pandolfi, P. P. Tenets of PTEN tumor suppression. Cell 2008, 133, 403-414.
235. Knight, Z. A.; Shokat, K. M. Chemically targeting the PI3K family. Biochem. Soc. Trans. 2007, 35(Pt 2), 245-249.
236. Rajesh, M.; Mukhopadhyay, P.; Godlewski, G.; Bátkai, S.; Haskó, G.; Liaudet, L.; Pacher, P. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350, 1056-1062.
237. Tentori, L.; Lacal, P. M.; Muzi, A.; Dorio, A. S.; Leonetti, C.; Scarsella, M.; Ruffini, F.; Xu, W.; Min, W.; Stoppacciaro, A.; Colarossi, C.; Wang, Z. Q.; Zhang, J.; Graziani, G. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 2007, 43, 2124-2133.
238. Pyriochou, A.; Olah, G.; Deitch, E. A.; Szabó, C.; Papapetropoulos, A. Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int. J. Mol. Med. 2008, 22, 113-118.
239. Lacal, P. M.; Tentori, L.; Muzi, A.; Ruffini, F.; Dorio, A. S.; Xu, W.; Arcelli, D.; Zhang, J.; Graziani, G. Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells. Int. J. Oncol. 2009, 34, 861-872.
240. Martin-Oliva, D.; Aguilar-Quesada, R.; O'valle, F.; Muñoz-Gámez, J. A.; Martínez-Romero, R.; García Del Moral, R.; Ruiz de Almodóvar, J. M.; Villuendas, R.; Piris, M. A.; Oliver, F. J. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006, 66, 5744-5756.
241. Lacal, P. M.; Morea, V.; Ruffini, F.; Orecchia, A.; Dorio, A. S.; Failla, C. M.; Soro, S.; Tentori, L.; Zambruno, G.; Graziani, G.; Tramontano, A.; D'Atri, S. Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide. Eur. J. Cancer 2008, 44, 1914-1921.
242. Tentori, L.; Muzi, A.; Dorio, A. S.; Bultrini, S.; Mazzon, E.; Lacal, P. M.; Shah, G. M.; Zhang, J.; Navarra, P.; Nocentini, G.; Cuzzocrea, S.; Graziani, G. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur. J. Cancer 2008, 44, 1302-1314.
243. Carlson, M. R.; Pope, W. B.; Horvath, S.; Braunstein, J. G.; Nghiemphu, P.; Tso, C. L.; Mellinghoff, I.; Lai, A.; Liau, L. M.; Mischel, P. S.; Dong, J.; Nelson, S. F.; Cloughesy, T. F. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin. Cancer Res. 2007, 13, 2592-2598.